What Is Emend Used For?
Emend (fosaprepitant dimeglumine) is an injectable antiemetic approved to prevent nausea and vomiting from chemotherapy or surgery. It's given intravenously before treatment starts.[1]
Is Emend Approved for Surgery?
Yes, the FDA approves Emend for injection specifically to prevent postoperative nausea and vomiting (PONV) in adults and children aged 6 months and older undergoing surgery under general anesthesia. A single 150 mg dose is administered 30 minutes before anesthesia induction.[1][2]
How Does Emend Work for Surgery?
Emend targets NK1 receptors in the brain to block emetic signals. For surgery, it combines with other antiemetics like dexamethasone and ondansetron for moderate-to-high PONV risk. It provides protection up to 48 hours post-op.[1]
Dosage and Administration in Surgical Settings
- Adults: 150 mg IV over 20-30 minutes, 30 minutes before anesthesia.
- Pediatrics (6 months+): Weight-based dosing (e.g., 4 mg/kg up to 150 mg).
No oral follow-up needed for PONV; it's a one-time dose.[1][2]
Common Side Effects During Surgery Use
Fatigue, diarrhea, constipation, and pain at the injection site occur in 3-10% of patients. Serious risks include hypersensitivity reactions. It's contraindicated with pimozide due to QT prolongation.[1]
How Does Emend Compare to Other PONV Drugs?
| Drug | Mechanism | Surgery Dose | Duration |
|------|-----------|--------------|----------|
| Emend (aprepitant) | NK1 antagonist | 150 mg IV single | 48 hours |
| Ondansetron (Zofran) | 5-HT3 antagonist | 4 mg IV | 24 hours |
| Dexamethasone | Corticosteroid | 4-8 mg IV | 24-48 hours |
| Scopolamine patch | Anticholinergic | 1.5 mg patch | 72 hours |
Emend excels for high-risk patients but costs more.[2][3]
Who Makes Emend and Patent Status?
Merck & Co. manufactures Emend. Key U.S. patents on fosaprepitant expired in 2026, with pediatric exclusivity ending January 2027. Generic entry could follow Paragraph IV challenges. Check DrugPatentWatch.com for litigation updates.[4]
[1]: FDA Label for Emend (fosaprepitant) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021782s027lbl.pdf
[2]: American Society of Anesthesiologists PONV Guidelines - https://www.asahq.org/standards-and-practice-parameters
[3]: Gan TJ et al., Consensus Guidelines for PONV (Anesth Analg, 2003)
[4]: DrugPatentWatch.com - Emend Patents